Need professional-grade analysis? Visit stockanalysis.com
$44.40B
19.28
14,500
1.97%
Zoetis Inc (ZOE) trades on XETRA (Frankfurt) in EUR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at EUR100.64, up 0.24% from the previous close.
Over the past year, ZOE has traded between a low of EUR99.32 and a high of EUR150.61. The stock has lost 31.9% over this period. It is currently 33.2% below its 52-week high.
Zoetis Inc has a market capitalization of $44.40B, with a price-to-earnings ratio of 19.28 and a dividend yield of 1.97%.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.